(NASDAQ:IKT), Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial […]

SLEEK signs long-term partnership to revolutionize digital culture with Universal Profiles on LUKSO GlobeNewswire November 20, 2025 ZUG, Switzerland, Nov. 20, 2025 (GLOBE NEWSWIRE) — SLEEK, the Berlin-based art and culture media platform, has entered a one-year partnership with the Foundation for the New Creative Economies (FNCE) to explore the future of digital culture through

Indivior PLC (Nasdaq: INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding obligation of $295 million associated with the matter. With the DOJ's receipt of the payment, the resolution agreement with the DOJ will be terminated. The payment was funded with Indivior's cash

— Compliancesolution available through S&P Global Market Intelligence addresses the growing need for private credit and CLO managers to report on increasingly complex loan portfolios — Real-time data streaming facilitates accuracy and timeliness for compliance tests — Hypothetical trade management supports cross-deal, cross-asset allocation and shell asset creation S&P Global (NYSE: SPGI)today announced the launch

American Healthcare REIT, Inc. (NYSE: AHR; the “Company”) announced today that it has commenced an underwritten public offering of 8,100,000shares of its common stock on a forward basis in connection with the forward sale agreement described below. https://mma.prnewswire.com/media/1641068/American_Healthcare_REIT_logo.jpg RBC Capital Markets is acting as the underwriter for the offering. In connection with the offering, the

Stepan Company(NYSE:SCL) today announced the successful closing, on November 14, 2025, of the sale of its subsidiary, Stepan Philippines Quaternaries, Inc. (SPQI), manufacturing assets located in Bauan, Batangas, Philippines to Masurf, Inc., a subsidiary of Musim Mas Holdings Pte. Ltd. This transaction fulfills SPQI's previously announced Asset Transfer Agreement, dated May 27, 2025, and underscores

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension GlobeNewswire November 20, 2025 Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”),

(NASDAQ:PRAX), BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that HCWainwright analyst Doug Tsao will host an expert call on Deep Dive into Praxis' Ulixacaltamide

(NASDAQ:KTTA),(NASDAQ:KTTAW), — Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months — — A second MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation has achieved stable disease and remains on trial for more than 6 months — —

(NasdaqGM:KROS), LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tender Offer”) to repurchase up to 10,950,165 shares of its common stock, at a fixed purchase price of $17.75 per share, for an aggregate purchase price